These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16454655)

  • 1. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer.
    Lubaroff DM; Konety B; Link BK; Ratliff TL; Madsen T; Shannon M; Ecklund D; Williams RD
    Hum Gene Ther; 2006 Feb; 17(2):220-9. PubMed ID: 16454655
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
    Theoret MR; Arlen PM; Pazdur M; Dahut WL; Schlom J; Gulley JL
    Clin Genitourin Cancer; 2007 Jun; 5(5):347-50. PubMed ID: 17645835
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.
    Lubaroff DM; Konety BR; Link B; Gerstbrein J; Madsen T; Shannon M; Howard J; Paisley J; Boeglin D; Ratliff TL; Williams RD
    Clin Cancer Res; 2009 Dec; 15(23):7375-80. PubMed ID: 19920098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine immunotherapy for prostate cancer: from mice to men.
    Lubaroff DM; Vaena D; Brown JA; Zehr P; Griffith KC; Brown E; Eastman J; Nepple K; Kattula A; Williams RD
    Immunol Res; 2014 Aug; 59(1-3):229-35. PubMed ID: 24847764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical safety of a viral vector based prostate cancer vaccine strategy.
    Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
    J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
    Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
    Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer vaccine--Northwest Biotherapeutics: CaPVax, DC1/HRPC, DCVax--Prostate.
    BioDrugs; 2002; 16(3):226-7. PubMed ID: 12102653
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 19. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA; Gulley JL; Arlen PM
    Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.
    Essand M
    Acta Oncol; 2005; 44(6):610-27. PubMed ID: 16165921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.